MedTrace Logo

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

NCT07408869 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-07-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.

Conditions

  • IgE-Mediated Hypersensitivity
  • IgE Mediated Food Allergy
  • IgE-Mediated Cow Milk Allergy

Interventions

BIOLOGICAL

Cizutamig

cizutamig will be dosed SC according to the assigned cohort

Sponsors & Collaborators

  • Candid Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408869 on ClinicalTrials.gov